Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study

Neurology

Volumn 73, Issue 18, 2009, Pages 1493-1500

  Pachner, Andrew R ^a   Warth, John D ^b   Pace, Amy ^b   Goelz, Susan ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BIOLOGICAL MARKER; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; PROTEIN; PROTEIN IFIT 1; UNCLASSIFIED DRUG; VIPER VENOM;

ADULT; AGED; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; SCREENING; TREATMENT WITHDRAWAL;

EID: 70449449076     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181bf98db     Document Type: Article

References (35)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
3. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon /3-1a in relapsing/ remitting multiple sclerosis. Lancet 1998;352:1498-1504.
4. Sondak VK, Redman BG. Pharmacology of cancer bio-therapeutics. In: Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, Williams & Wilkins; 2005.
5. Domanski P, Witte M, Kellum M, et al. Cloning and expression of a long form of the /3 subunit of the interferon a/3 receptor that is required for signaling. J Biol Chem 1995;270:21606-21611.
6. Javed A, Reder AT. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther 2006;110:35-56.
7. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon /3 bioavailability in MS patients. Neurology 2003;60:634-639.
8. Gilli F, Marnetto F, Caldano M, et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 2006;12:47-57.
9. Scagnolari C, Duda P, Bagnato F, et al. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol 2007;254:597-604.
10. Chin KC, Cresswell P. Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc Natl Acad Sci USA 2001;98:15125-15130.
11. Rivieccio MA, Suh HS, Zhao Y, et al. TLR3 ligation activates an antiviral response in human fetal astrocytes: a role for viperin/cig5. J Immunol 2006;177:4735-4741.
12. Severa M, Coccia EM, Fitzgerald KA. Toll-like receptor-dependent and-independent viperin gene expression and counter-regulation by PRDI-binding factor-1/BLIMP1. J Biol Chem 2006;281:26188-26195.
13. Ye S, Pang H, Gu Y, et al. Protein interaction for an interferon-inducible systemic lupus associated gene, IFIT1. Rheumatology 2003;42:1155-1163.
14. Pachner AR, Narayan K, Price N, et al. MxA gene expression analysis as an interferon-/3 bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003;7:17-25.
15. Pachner AR, Narayan K, Pak E. Multiple analysis of expression of three IFN/3-induced genes in antibody-positive MS patients. Neurology 2006;66:444-446.
16. Francis GS, Rice GP, Alsop JC, et al. Interferon /3-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005;65:48-55.
17. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon /3-1a: a 4-year controlled study. Neurology 2005;65:40-47.
18. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-1191.
19. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008;70:1069-1070.
20. Sorensen PS, Tscherning T, Mathiesen HK, et al. Neutralizing antibodies hamper IFN beta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006; 67:1681-1683.
21. Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001;CD002002.
22. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. The neutralization of interferons by antibody, 1: quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 2001;21:729-742.
23. Brickelmaier M, Hochman PS, Baciu R, Chao B, Cuervo JH, Whitty A. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-h. J Immunol Methods 1999;227:121-135.
24. Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 2003;61:1444-1446.
25. Pachner AR, Dail D, Pak E, et al. The importance of measuring IFN/3 bioactivity: monitoring in MS patients and the effect of anti-IFN/3 antibodies. J Neuroimmunol 2005;166:180-188.
26. Prince HE, Lape-Nixon M, Audette C, et al. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera. J Neuroimmunol 2007;190:165-169
27. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894.
28. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148-153.
29. Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-39.
30. Cook SD, Quinless JR, Jotkowitz A, et al. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 2001;57:1080-1084.
31. Sominanda A, Rot U, Suoniemi M, et al. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immu-nogenicity. Mult Scler 2007;13:208-214.
32. Ross C, Clemmesen KM, Svenson M, et al. Immunogenic-ity of interferon-jS in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000;48:706-712.
33. Deisenhammer F, Reindl M, Harvey J, et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52: 1239-1243.
34. Santos R, Weinstock-Guttman B, Tamano-Blanco M, et al. Dynamics of interferon-/3 modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-/3 neutralizing antibodies. J Neuroimmunol 2006;176:125-133.
35. Rudick RA. Biologic impact of interferon antibodies, and complexities in assessing their clinical significance. Neurology 2003;61(suppl 5):S29-S32